Melatonin oral gel

Drug Profile

Melatonin oral gel

Alternative Names: JAN-13004; SP-13004

Latest Information Update: 21 Oct 2015

Price : $50

At a glance

  • Originator Spherium Biomed
  • Class Hormones; Sleep disorder therapies; Tryptamines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Stomatitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 02 Oct 2015 Phase-I/II clinical trials in Stomatitis (Chemotherapy-induced) in Spain (PO) (EudraCT2015-001534-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top